ERBB2 and breast cancer: The introduction of trastuzumab, the humanized anti-HER2 monoclonal antibody, and the subsequent development of other anti-HER2 agents (i.e., lapatinib, pertuzumab, T-DM1 and T-Dxd) have drastically improved prognosis of HER2-positive BC patients.